Pioneering Differentiated TCR T Therapies for Cancer Patients
Medigene is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Medigene was founded by scientists with the commitment to create breakthrough therapies to fundamentally improve the lives of cancer patients.
Medigene’s End-to-End Platform
The basis of Medigene’s differentiation is our end-to-end platform of multiple, combinable, exclusive and proprietary technologies. These technologies build in both the potential of enhancing our TCR-T drug products from a safety and / or efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.
TCR-T Therapy Optimization
Manufacturing Scale-Up and Process Improvement
MDG1015: BRINGING OUR TCR THERAPIES TO PATIENTS
3rd generation NY-ESO-1 targeted TCR-T therapy combined with our PD1-41BB switch receptor – a sensitive, specific TCR with a favorable safety profile
Medigenes end-to-end platform allows to develop highly innovative, complementary treatment platforms for the treatment of various cancer types
Our TCR Technology
Our end-to-end platform enables us to generate TCR- T cells with high sensitivity, specificity and safety
We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.